Atalanta
41 employees on LinkedIn · 9 known investors
Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology. The company was founded by leading experts in RNAi research.
Investors · 9
F-Prime CapitalCambridge · $3M – $10M
Novartis Venture FundBasel · $5M – $25M
RiverVest Venture PartnersSt. Louis · $500K – $3M
Sanofi VenturesCambridge · $5M
abrdn plcreportedEdinburgh
EQT Life Sciencesreported · 2 sourcesLuxembourg · $11M – $66M
Also in the syndicate · 3
GHR FoundationMirae Asset Financial GroupPictet Alternative Advisors
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BFeb 2025
EQT Life Sciences (lead), Sanofi Ventures (lead), abrdn, F-Prime Capital, GHR Foundation, Mirae Asset Financial Group, Novartis Venture Fund, Pictet Alternative Advisors, RiverVest Venture Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Atalanta do?
- Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology. The company was founded by leading experts in RNAi research.
- Who are Atalanta's investors?
- Atalanta's investors include F-Prime Capital, Novartis Venture Fund, RiverVest Venture Partners, Sanofi Ventures, abrdn plc, EQT Life Sciences.